Press releases
These press releases are intended for journalists and analysts/investors.
-
INTERNATIONAL MEN’S HEALTH WEEK 2015: Sam Newman exposes neglected men’s health issue
Australian campaign focuses on enlarged prostates
-
GSK Australia launches new vaccination picture book for Aboriginal and Torres Strait Islanders
GSK Australia has a new immunisation resource for Aboriginal and Torres Strait Islanders this month to encourage families to be proactive
-
GSK granted $1 million by Federal Government for advanced manufacturing project in Boronia
GSK Australia is a recipient of a grant through of the Federal Government’s Manufacturing Transition Programme worth AUD$1 million
-
GSK Australia Reports 2014 results to ASIC
GlaxoSmithKline (GSK) Australia reported to the Australian Securities and Investment Commission (ASIC) sales revenue of $906m in 2014
-
GSK Award for Research Excellence opens
Nominations for GSK’s Award for Research Excellence (ARE) open today for the 35th year running
-
Supply update: Fluarix Tetra and Fluarix
GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia
-
GSK discloses payments to Australian healthcare professionals in 2014
In 2014, GSK Australia made payments totalling $3,466,951 to healthcare professionals (HCPs) and health-related organisations
-
GSK responds to devastation in Vanuatu
GSK provides £50,000 donation to Save the Children to support relief efforts following Tropical Cyclone Pam
-
Sun Pharma to buy GSK’s Opiates business in Australia
The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria)
-
GSK completes major three-part transaction with Novartis
GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis has completed today
-
Supply update: Zovirax Ophthalmic Ointment (aciclovir 3%) (1)
Regrettably, Zovirax Ophthalmic Ointment (aciclovir 3%) continues to be impacted by a global supply constraint
-
GSK statement on affordability of vaccines in developing countries
More children from the world’s poorest countries are being vaccinated against more diseases than ever before
-
Adelaide Hills Bushfires: Donation of asthma medication
GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas
-
Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS)
-
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed
-
Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD
Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand
-
GSK announces multi-million dollar investment in next generation manufacturing
GSK Australia has announced today it will be investing AUD$31 million in next generation manufacturing technology
-
Indigenous and refugee programs win immunisation boost
Winners are from across Australia and include medical groups in Mildura, Townsville, Geraldton and Brisbane. They each receive $20,000
-
GSK transitions to online versions of Consumer Medicine Information (CMI) leaflets for prescription only medicines
To ensure we provide the most up-to-date consumer medicine information (CMI) to patients, GSK will no longer be providing CMI leaflets
-
Plant drugs and snail venom: Revolutionary drug research wins GSK award
Plants with peptide-based drugs in their seeds and leaves, and pain relief from cone snail venom are two of the innovative applications